BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that independent researchers today presented results showing that XOMA's antibody to interleukin-1 beta , XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

Topics:  calif    xoma ltd   xoma   vitro   production   human myeloma cells   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News